A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.

@article{Goldstein2017APA,
  title={A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.},
  author={Daniel A Goldstein and Noa Gordon and Michal Davidescu and Moshe M Leshno and Conor Ernst Steuer and Nikita M. Patel and Salomon Marcello Stemmer and Alona Zer},
  journal={Journal of the National Cancer Institute},
  year={2017},
  volume={109 11}
}
Background In October 2016, pembrolizumab became the new standard of care for firstline treatment of patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors express programmed death ligand 1 in at least 50% of cells. The US Food and Drug Administration-recommended dose is 200 mg every three weeks. Multiple studies have demonstrated equivalent efficacy with weight-based doses between 2 mg/kg and 10 mg/kg. The objective of this study was to compare the economic impact of using… CONTINUE READING
BETA

Similar Papers

Figures, Tables, and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

Cancer statistics ,

M Reck, D Rodriguez-Abreu, AG Robinson
  • 2016
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

SEER Cancer Statistics Review, 19752013

N Howlader, AM Noone, M Krapcho
  • Bethesda, MD: National Cancer Institute;
  • 2013
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2013
VIEW 2 EXCERPTS
HIGHLY INFLUENTIAL

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
VIEW 2 EXCERPTS
HIGHLY INFLUENTIAL

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2017
VIEW 1 EXCERPT